German recommendations on health economic evaluation: Third and updated version of the Hanover Consensus

von der Schulenburg J-MG, Greiner W, Jost F, Klusen N, Kubin M, Leidl R, Mittendorf T, Rebscher H, Schoeffski O, Vauth C, Volmer T, et al. (2008)
VALUE IN HEALTH 11(4): 539-544.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
 
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
DOI
Autor*in
von der Schulenburg, J. -Matthias Graf; Greiner, WolfgangUniBi; Jost, Fred; Klusen, Norbert; Kubin, Maria; Leidl, Reiner; Mittendorf, Thomas; Rebscher, Herbert; Schoeffski, Oliver; Vauth, Christoph; Volmer, Timm; Wahler, Steffen
Alle
Einrichtung
Fakultät für Gesundheitswissenschaften
Stichworte
guidelines; health-care services research; health; economic guidelines; health-care analyses
Erscheinungsjahr
2008
Zeitschriftentitel
VALUE IN HEALTH
Band
11
Ausgabe
4
Seite(n)
539-544
ISSN
1098-3015
Page URI
https://pub.uni-bielefeld.de/record/1586740

Zitieren

von der Schulenburg J-MG, Greiner W, Jost F, et al. German recommendations on health economic evaluation: Third and updated version of the Hanover Consensus. VALUE IN HEALTH. 2008;11(4):539-544.
von der Schulenburg, J. - M. G., Greiner, W., Jost, F., Klusen, N., Kubin, M., Leidl, R., Mittendorf, T., et al. (2008). German recommendations on health economic evaluation: Third and updated version of the Hanover Consensus. VALUE IN HEALTH, 11(4), 539-544. https://doi.org/10.1111/j.1524-4733.2007.00301.x
von der Schulenburg, J. -Matthias Graf, Greiner, Wolfgang, Jost, Fred, Klusen, Norbert, Kubin, Maria, Leidl, Reiner, Mittendorf, Thomas, et al. 2008. “German recommendations on health economic evaluation: Third and updated version of the Hanover Consensus”. VALUE IN HEALTH 11 (4): 539-544.
von der Schulenburg, J. - M. G., Greiner, W., Jost, F., Klusen, N., Kubin, M., Leidl, R., Mittendorf, T., Rebscher, H., Schoeffski, O., Vauth, C., et al. (2008). German recommendations on health economic evaluation: Third and updated version of the Hanover Consensus. VALUE IN HEALTH 11, 539-544.
von der Schulenburg, J.-M.G., et al., 2008. German recommendations on health economic evaluation: Third and updated version of the Hanover Consensus. VALUE IN HEALTH, 11(4), p 539-544.
J.-M.G. von der Schulenburg, et al., “German recommendations on health economic evaluation: Third and updated version of the Hanover Consensus”, VALUE IN HEALTH, vol. 11, 2008, pp. 539-544.
von der Schulenburg, J.-M.G., Greiner, W., Jost, F., Klusen, N., Kubin, M., Leidl, R., Mittendorf, T., Rebscher, H., Schoeffski, O., Vauth, C., Volmer, T., Wahler, S., Wasem, J., Weber, C.: German recommendations on health economic evaluation: Third and updated version of the Hanover Consensus. VALUE IN HEALTH. 11, 539-544 (2008).
von der Schulenburg, J. -Matthias Graf, Greiner, Wolfgang, Jost, Fred, Klusen, Norbert, Kubin, Maria, Leidl, Reiner, Mittendorf, Thomas, Rebscher, Herbert, Schoeffski, Oliver, Vauth, Christoph, Volmer, Timm, Wahler, Steffen, Wasem, Juergen, and Weber, Christian. “German recommendations on health economic evaluation: Third and updated version of the Hanover Consensus”. VALUE IN HEALTH 11.4 (2008): 539-544.

70 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

A systematic review of pharmacoeconomic guidelines.
Zhao Y, Feng HM, Qu J, Luo X, Ma WJ, Tian JH., J Med Econ 21(1), 2018
PMID: 28959910
Vaginal birth after caesarean versus elective repeat caesarean delivery after one previous caesarean section: a cost-effectiveness analysis in four European countries.
Fobelets M, Beeckman K, Faron G, Daly D, Begley C, Putman K., BMC Pregnancy Childbirth 18(1), 2018
PMID: 29642858
Patient trajectories and their impact on mobility, social participation and quality of life in patients with vertigo/dizziness/balance disorders and osteoarthritis (MobilE-TRA): study protocol of an observational, practice-based cohort study.
Kisch R, Bergmann A, Koller D, Leidl R, Mansmann U, Mueller M, Sanftenberg L, Schelling J, Sundmacher L, Voigt K, Grill E., BMJ Open 8(4), 2018
PMID: 29680815
Friction Cost Estimates of Productivity Costs in Cost-of-Illness Studies in Comparison with Human Capital Estimates: A Review.
Pike J, Grosse SD., Appl Health Econ Health Policy 16(6), 2018
PMID: 30094591
The economic burden of adult asthma in Cyprus; a prevalence-based cost of illness study.
Zannetos S, Zachariadou T, Zachariades A, Georgiou A, Talias MA., BMC Public Health 17(1), 2017
PMID: 28302094
Cost-effectiveness of timely versus delayed primary total hip replacement in Germany: A social health insurance perspective.
Mujica-Mota RE, Watson LK, Tarricone R, Jäger M., Orthop Rev (Pavia) 9(3), 2017
PMID: 29071040
Cost-effectiveness of human papillomavirus vaccination in Germany.
Damm O, Horn J, Mikolajczyk RT, Kretzschmar MEE, Kaufmann AM, Deleré Y, Ultsch B, Wichmann O, Krämer A, Greiner W., Cost Eff Resour Alloc 15(), 2017
PMID: 28878573
Estimating productivity costs using the friction cost approach in practice: a systematic review.
Kigozi J, Jowett S, Lewis M, Barton P, Coast J., Eur J Health Econ 17(1), 2016
PMID: 25387561
Health economic analyses of psoriasis management: a systematic literature search.
Gutknecht M, Krensel M, Augustin M., Arch Dermatol Res 308(9), 2016
PMID: 27435415
Neurologist adherence to clinical practice guidelines and costs in patients with newly diagnosed and chronic epilepsy in Germany.
Strzelczyk A, Bergmann A, Biermann V, Braune S, Dieterle L, Forth B, Kortland LM, Lang M, Peckmann T, Schöffski O, Sigel KO, Rosenow F., Epilepsy Behav 64(pt a), 2016
PMID: 27732920
Evolution of cost structures in rheumatoid arthritis over the past decade.
Huscher D, Mittendorf T, von Hinüber U, Kötter I, Hoese G, Pfäfflin A, Bischoff S, Zink A, German Collaborative Arthritis Centres., Ann Rheum Dis 74(4), 2015
PMID: 24406543
Evaluation of costs of epilepsy using an electronic practice management software in Germany.
Noda AH, Hermsen A, Berkenfeld R, Dennig D, Endrass G, Kaltofen J, Safavi A, Wiehler S, Carl G, Meier U, Elger CE, Menzler K, Knake S, Rosenow F, Strzelczyk A., Seizure 26(), 2015
PMID: 25799902
Economic and clinical aspects of intravenous versus oral busulfan in adult patients for conditioning prior to HSCT.
Berger K, Schopohl D, Rieger C, Ostermann H., Support Care Cancer 23(12), 2015
PMID: 25773673
Cost for physician-diagnosed influenza and influenza-like illnesses on primary care level in Germany--results of a database analysis from May 2010 to April 2012.
Ehlken B, Anastassopoulou A, Hain J, Schröder C, Wahle K., BMC Public Health 15(), 2015
PMID: 26093501
Costs of epilepsy and cost-driving factors in children, adolescents, and their caregivers in Germany.
Riechmann J, Strzelczyk A, Reese JP, Boor R, Stephani U, Langner C, Neubauer BA, Oberman B, Philippi H, Rochel M, Seeger J, Seipelt P, Oertel WH, Dodel R, Rosenow F, Hamer HM, EpiPaed Study Group., Epilepsia 56(9), 2015
PMID: 26235849
First outline and baseline data of a randomized, controlled multicenter trial to evaluate the health economic impact of home telemonitoring in chronic heart failure - CardioBBEAT.
Hofmann R, Völler H, Nagels K, Bindl D, Vettorazzi E, Dittmar R, Wohlgemuth W, Neumann T, Störk S, Bruder O, Wegscheider K, Nagel E, Fleck E, CardioBBEAT Investigators., Trials 16(), 2015
PMID: 26259568
Adherence and cost in multiple sclerosis patients treated with IM IFN beta-1a: impact of the CARE patient management program.
Katsarava Z, Ehlken B, Limmroth V, Taipale K, Patel SN, Niemczyk G, Rehberg-Weber K, Wernsdörfer C, C.A.R.E. Study Group., BMC Neurol 15(), 2015
PMID: 26395989
Effectiveness of a brief psychoeducational group intervention for relatives on the course of disease in patients after inpatient depression treatment compared with treatment as usual--study protocol of a multisite randomised controlled trial.
Frank F, Wilk J, Kriston L, Meister R, Shimodera S, Hesse K, Bitzer EM, Berger M, Hölzel LP., BMC Psychiatry 15(), 2015
PMID: 26497218
The cost-utility of open prostatectomy compared with active surveillance in early localised prostate cancer.
Koerber F, Waidelich R, Stollenwerk B, Rogowski W., BMC Health Serv Res 14(), 2014
PMID: 24721557
Evaluation of health-care utilization in patients with Dravet syndrome and on adjunctive treatment with stiripentol and clobazam.
Strzelczyk A, Schubert-Bast S, Reese JP, Rosenow F, Stephani U, Boor R., Epilepsy Behav 34(), 2014
PMID: 24727467
The economic burden of schizophrenia in Germany: a population-based retrospective cohort study using genetic matching.
Frey S., Eur Psychiatry 29(8), 2014
PMID: 24853296
Should health insurers target prevention of cardiovascular disease? A cost-effectiveness analysis of an individualised programme in Germany based on routine data.
Aljutaili M, Becker C, Witt S, Holle R, Leidl R, Block M, Brachmann J, Silber S, Bestehorn K, Stollenwerk B., BMC Health Serv Res 14(), 2014
PMID: 24938674
Economic burden of inadequate management of allergic diseases in the European Union: a GA(2) LEN review.
Zuberbier T, Lötvall J, Simoens S, Subramanian SV, Church MK., Allergy 69(10), 2014
PMID: 24965386
Cost of multi drug resistance tuberculosis in Germany.
Diel R, Nienhaus A, Lampenius N, Rüsch-Gerdes S, Richter E., Respir Med 108(11), 2014
PMID: 25443398
Annual cost of hospitalization, inpatient rehabilitation and sick leave of anal cancer in Germany.
Heitland W, Schädlich PK, Chen X, Rémy V, Moro L., J Med Econ 16(3), 2013
PMID: 23253056
Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in Germany.
Strzelczyk A, Haag A, Reese JP, Nickolay T, Oertel WH, Dodel R, Knake S, Rosenow F, Hamer HM., Epilepsy Behav 27(3), 2013
PMID: 23591262
Annual cost of hospitalization, inpatient rehabilitation, and sick leave for head and neck cancers in Germany.
Klussmann JP, Schädlich PK, Chen X, Rémy V., Clinicoecon Outcomes Res 5(), 2013
PMID: 23717047
The association of smoking status with healthcare utilisation, productivity loss and resulting costs: results from the population-based KORA F4 study.
Wacker M, Holle R, Heinrich J, Ladwig KH, Peters A, Leidl R, Menn P., BMC Health Serv Res 13(), 2013
PMID: 23866993
The EVIDENT-trial: protocol and rationale of a multicenter randomized controlled trial testing the effectiveness of an online-based psychological intervention.
Klein JP, Berger T, Schröder J, Späth C, Meyer B, Caspar F, Lutz W, Greiner W, Hautzinger M, Rose M, Gräfe V, Hohagen F, Andersson G, Vettorazzi E, Moritz S., BMC Psychiatry 13(), 2013
PMID: 24074299
[Cost-effectiveness analysis of immunosuppressive drugs in post-renal transplantation maintenance therapy in adult patients in Brazil].
Acurcio Fde A, Saturnino LT, Silva AL, Oliveira GL, Andrade EI, Cherchiglia ML, Ceccato Md., Cad Saude Publica 29 Suppl 1(), 2013
PMID: 25402255
Towards a social discount rate for the economic evaluation of health technologies in Germany: an exploratory analysis.
Schad M, John J., Eur J Health Econ 13(2), 2012
PMID: 21170731
Why is it so difficult to evaluate nursing interventions in dementia?
Schwarzbach C, Förstl H, Nocon M, Mittendorf T., Dement Geriatr Cogn Dis Extra 2(), 2012
PMID: 22590475
Potential cost-effectiveness and benefit-cost ratios of adult pneumococcal vaccination in Germany.
Kuhlmann A, Theidel U, Pletz MW, von der Schulenburg JM., Health Econ Rev 2(1), 2012
PMID: 22828176
Cost-effectiveness of TNF-α inhibition in active ankylosing spondylitis: a systematic appraisal of the literature.
Kirchhoff TD, Mittendorf T, Schmidt RE, Jablonka A, Merkesdal S., Expert Rev Pharmacoecon Outcomes Res 12(3), 2012
PMID: 22812555
[Patients suffering from atrial fibrillation in Germany. Characteristics, resource consumption and costs].
Reinhold T, Rosenfeld S, Müller-Riemenschneider F, Willich SN, Meinertz T, Kirchhof P, Brüggenjürgen B., Herz 37(5), 2012
PMID: 22301729
Health economic evaluation of insulin glargine vs NPH insulin in intensified conventional therapy for type 1 diabetes in Germany.
Pfohl M, Schädlich PK, Dippel FW, Koltermann KC., J Med Econ 15 Suppl 2(), 2012
PMID: 22812690
Cost of illness of cystic fibrosis in Germany: results from a large cystic fibrosis centre.
Heimeshoff M, Hollmeyer H, Schreyögg J, Tiemann O, Staab D., Pharmacoeconomics 30(9), 2012
PMID: 22690685
A lifetime Markov model for the economic evaluation of chronic obstructive pulmonary disease.
Menn P, Leidl R, Holle R., Pharmacoeconomics 30(9), 2012
PMID: 22799876
Specific guidelines for assessing and improving the methodological quality of economic evaluations of newborn screening.
Langer A, Holle R, John J., BMC Health Serv Res 12(), 2012
PMID: 22947299
Practical issues in handling data input and uncertainty in a budget impact analysis.
Nuijten MJ, Mittendorf T, Persson U., Eur J Health Econ 12(3), 2011
PMID: 20364289
Health burden and costs of obesity and overweight in Germany.
Konnopka A, Bödemann M, König HH., Eur J Health Econ 12(4), 2011
PMID: 20401679
Cost of low back pain in Switzerland in 2005.
Wieser S, Horisberger B, Schmidhauser S, Eisenring C, Brügger U, Ruckstuhl A, Dietrich J, Mannion AF, Elfering A, Tamcan O, Müller U., Eur J Health Econ 12(5), 2011
PMID: 20526649
Nutrition economics - characterising the economic and health impact of nutrition.
Lenoir-Wijnkoop I, Dapoigny M, Dubois D, van Ganse E, Gutiérrez-Ibarluzea I, Hutton J, Jones P, Mittendorf T, Poley MJ, Salminen S, Nuijten MJ., Br J Nutr 105(1), 2011
PMID: 20797310
Health care costs and their predictors of inflammatory bowel diseases in Germany.
Prenzler A, Bokemeyer B, von der Schulenburg JM, Mittendorf T., Eur J Health Econ 12(3), 2011
PMID: 20967482
Cost of illness in rheumatoid arthritis in Germany in 1997-98 and 2002: cost drivers and cost savings.
Kirchhoff T, Ruof J, Mittendorf T, Rihl M, Bernateck M, Mau W, Zeidler H, Schmidt RE, Merkesdal S., Rheumatology (Oxford) 50(4), 2011
PMID: 21149243
Service use and costs of incident femoral fractures in nursing home residents in Germany: the Bavarian Fall and Fracture Prevention Project (BF2P2).
Heinrich S, Rapp K, Rissmann U, Becker C, König HH., J Am Med Dir Assoc 12(6), 2011
PMID: 21450261
Health resource consumption and costs attributable to chemotherapy-induced toxicity in German routine hospital care in lymphoproliferative disorder and NSCLC patients.
Paessens BJ, von Schilling C, Berger K, Shlaen M, Müller-Thomas C, Bernard R, Peschel C, Ihbe-Heffinger A., Ann Oncol 22(10), 2011
PMID: 21343378
Association of IGF-I and IGFBP-3 with health care costs and hospitalization: results from a prospective observational study.
Baumeister SE, Friedrich N, Schmidt CO, Völzke H, Nauck M, Hoffmann W, Flessa S, Marschall P, Wallaschofski H., Growth Horm IGF Res 21(2), 2011
PMID: 21393039
Economic burden of vulvar and vaginal intraepithelial neoplasia: retrospective cost study at a German dysplasia centre.
Hampl M, Huppertz E, Schulz-Holstege O, Kok P, Schmitter S., BMC Infect Dis 11(), 2011
PMID: 21426562
Do economic evaluations of targeted therapy provide support for decision makers?
Ferrusi IL, Leighl NB, Kulin NA, Marshall DA., Am J Manag Care 17 Suppl 5 Developing(), 2011
PMID: 21711079
Do economic evaluations of targeted therapy provide support for decision makers?
Ferrusi IL, Leighl NB, Kulin NA, Marshall DA., J Oncol Pract 7(3 suppl), 2011
PMID: 21886518
Cost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazine.
Prenzler A, Yen L, Mittendorf T, von der Schulenburg JM., BMC Health Serv Res 11(), 2011
PMID: 21729262
Systematic review of cost and cost-effectiveness of different TB-screening strategies.
Nienhaus A, Schablon A, Costa JT, Diel R., BMC Health Serv Res 11(), 2011
PMID: 21961888
Cost-of-illness of patients with chronic hand eczema in routine care: results from a multicentre study in Germany.
Augustin M, Kuessner D, Purwins S, Hieke K, Posthumus J, Diepgen TL., Br J Dermatol 165(4), 2011
PMID: 21623744
Cost-effectiveness of insulin detemir: a systematic review.
Suh DC, Aagren M., Expert Rev Pharmacoecon Outcomes Res 11(6), 2011
PMID: 21961796
Costing of physical activity programmes in primary prevention: a review of the literature.
Wolfenstetter SB, Wenig CM., Health Econ Rev 1(1), 2011
PMID: 22827967
Economic burden in a German cohort of patients with multiple sclerosis.
Reese JP, John A, Wienemann G, Wellek A, Sommer N, Tackenberg B, Balzer-Geldsetzer M, Dodel R., Eur Neurol 66(6), 2011
PMID: 22086151
Conceptual framework for standard economic evaluation of physical activity programs in primary prevention.
Wolfenstetter SB., Prev Sci 12(4), 2011
PMID: 21773728
Economic evaluation and transferability of physical activity programmes in primary prevention: a systematic review.
Wolfenstetter SB, Wenig CM., Int J Environ Res Public Health 7(4), 2010
PMID: 20617050
Cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in Germany.
Neilson AR, Sieper J, Deeg M., Rheumatology (Oxford) 49(11), 2010
PMID: 20660498
The transferability of valuing lost productivity across jurisdictions. differences between national pharmacoeconomic guidelines.
Knies S, Severens JL, Ament AJ, Evers SM., Value Health 13(5), 2010
PMID: 20712601
General population versus disease-specific event rate and cost estimates: potential bias for economic appraisals.
Goeree R, O'Reilly D, Hopkins R, Blackhouse G, Tarride JE, Xie F, Lim M., Expert Rev Pharmacoecon Outcomes Res 10(4), 2010
PMID: 20715915
Health technology assessment and economic evaluation: arguments for a national approach.
Vale L., Value Health 13(6), 2010
PMID: 20701729
Cost comparison of insulin glargine with insulin detemir in a basal-bolus regime with mealtime insulin aspart in type 2 diabetes in Germany.
Pscherer S, Dietrich ES, Dippel FW, Neilson AR., Ger Med Sci 8(), 2010
PMID: 20725588
Prospective association of low serum total testosterone levels with health care utilization and costs in a population-based cohort of men.
Haring R, Baumeister SE, Völzke H, Kohlmann T, Marschall P, Flessa S, Nauck M, Wallaschofski H., Int J Androl 33(6), 2010
PMID: 20059581
Methods of economic evaluation for the German statutory healthcare system.
Mittendorf T, Greiner W, von der Schulenburg JM., Pharmacoeconomics 27(3), 2009
PMID: 19354346
Cost-effectiveness of insulin detemir compared with neutral protamine Hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in five European countries.
Gschwend MH, Aagren M, Valentine WJ., J Med Econ 12(2), 2009
PMID: 19545216
Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting.
Mittendorf T, Smith-Palmer J, Timlin L, Happich M, Goodall G., Diabetes Obes Metab 11(11), 2009
PMID: 19732121
Cost Effectiveness of Exemestane versus Tamoxifen in Post-Menopausal Women with Early Breast Cancer in Germany.
Braun S, Mittendorf T, Menschik T, Greiner W, von der Schulenburg JM., Breast Care (Basel) 4(6), 2009
PMID: 20877674
Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a german perspective.
Liedgens H, Hertel N, Gabriel A, Nuijten M, Dakin H, Mitchell S, Nautrup BP., Clin Drug Investig 28(9), 2008
PMID: 18666805

References

Daten bereitgestellt von Europe PubMed Central.

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®
Quellen

PMID: 18194408
PubMed | Europe PMC

Suchen in

Google Scholar